目的：比较分析国内外关于临床试验期间安全性定期报告的相关法规和指导原则要求的异同点， 为加强我国试验用新药临床试验期间安全性定期报告的管理提供理论依据。方法：采用文献对比方法， 通过比较ICH、美国、欧盟、中国在临床试验期间安全性定期报告相关法规及指导原则情况，分析各国家/地区对试验用药物临床试验期间安全性报告监管要求的差异。结果与结论：在试验用药物临床试验期间的安全性定期报告方面，我国、FDA、欧盟均提出了明确的监管要求。各国家/地区均接受ICH E2F研发期间安全性更新报告的格式、内容及报告周期的要求，但在区域附件部分，各国家/地区均有各自的特殊要求。
Objective: By comparing and analyzing the similarities and diff erences between domestic and foreign regulations and guidelines on periodic safety reports during clinical trials, this study is to provide theoretical references for strengthening the management of periodic safety reports during clinical trials of investigational new drugs in China. Methods: With literature comparison method, the diff erences of regulatory requirements for periodic safety reports during clinical trials of investigational drugs in various countries/regions were analyzed by comparing the relevant regulations and guidelines for periodic safety reports during clinical trials in ICH, USA, EU and China. Results and Conclusion: In terms of periodic safety reports during clinical trials of new drugs, China, FDA and EU have all issued clear regulatory requirements. Each country/region has accepted the format, content and the regular reporting requirement of ICH E2F safety update reports during development, but each has its own special requirements in the regional annex.
[1] 中共中央办公厅,国务院办公厅.关于深化审评审批制度改革鼓励药品医疗器械创新的意见 [EB/OL].(2017-10-08)[2021-10-20].http://www.gov.cn/zhengce/2017-10/08/content_5230105.htm.
[2] 中华人民共和国全国人民代表大会常务委员会.中华人民共和国药品管理法[EB/OL].[2021-11-10].http://www.gov.cn/xinwen/2019-08/26/content_5424780.htm.
[3] ICH.ICH E2F Development Safety Update Report[EB/OL].[2021-11-10].https://database.ich.org/sites/default/files/E2F_Guideline.pdf.
[4] ICH.E6(R2)Integrated Addendum to ICH E6(R1):Guidline for Good Clinical Practice[EB/OL].[2021-11-10].https://database.ich.org/sites/default/files/E6_R2_Addendum.pdf.
[5] FDA.FDA 21 CFR 312 FDA Investigational New Drug Application[EB/OL].[2021-11-10].https://www.ecfr.gov/cgi-bin/text-idx?SID=0d59470d8438703d8924ae 3e7069dd87&mc=true&node=pt21.5.312&rgn=div5# se21.5.312_132.
[6] FDA.FDA Guidance for Industry and Investigators Safety Reporting Requirements for INDs and BA/BE Studies[EB/OL].[2021-11-10].https://www.fda.gov/media/79394/download.
[7] EMA.Communication from the Commission-Detailed Guidance on the Collection,Verification and Presentation of Adverse Event/Reaction Reports Arising from Clinical Trials on Medicinal Products for Human Use(‘CT3’)(2011/C 172/01)[EB/OL].[2021-11-10].https://ec.europa.eu/health/sites/health/files/files/clinicaltrials/ct3_resp/ema_2.pdf.
[8] EMA.Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community Code Relating to Medicinal Products for Human Use(OJ L 311,28.11.2001,p 85)[EB/OL].[2021-11-10].https://ww.ema.europa.eu/en/human-regulatory/researchdevelopment/clinical-trials-human-medicines.
[9] 国家药品监督管理局.国家药品监督管理局关于调整药物临床试验审评审批程序的公告(2018年第50号)[EB/OL].[2021-11-10].https://www.cfdi.org.cn/resource/news/10628.html.
[10] 药品审评中心.研发期间安全性更新报告要求及管理规定(试行)[EB/OL].[2021-11-10].http://www.cde.org.cn/news.do?method=largeInfo&id=3cad3925b893ab31.
[11] CIOMS Working Group VII.The Development Safety Update Report(DSUR):Harmonizing the Format and Content for Periodic Safety Reporting During Clinical Trials:Report of CIOMS Working Group VII[EB/OL].[2021-11-10].https://cioms.ch/publications/product/developmentsafety-update-report-dsur-harmonizing-format-contentperiodic-safety-report-clinical-trials-report-ciomsworking-group-vii/.
[12] 国家药品监督管理局.关于适用《E1:人群暴露程度:评估非危及生命性疾病长期治疗药物的临床安全性》 等15个国际人用药品注册技术协调会指导原则的公告 [EB/OL].[2021-11-10].https://www.nmpa.gov.cn/yaopin/ypggtg/ypqtgg/20191112094101469.html.
[13] 国家市场监督管理总局.药品注册管理办法[EB/OL].[2021-11-10].https://www.nmpa.gov.cn/xxgk/fgwj/bmgzh/20200330180501220.html.
[14] 国家药品监督管理局.国家药监局关于发布《药物警戒质量管理规范》的公告(2021年第65号)[EB/OL].[2021-11-10].https://www.nmpa.gov.cn/xxgk/ggtg/qtggtg/20210513151827179.html.
[15] 药品审评中心.关于公开征求ICH M8(eCTD)相关文件和ICH E2F示例中文翻译稿意见的通知[EB/OL].[2021-11-10].https://www.cde.org.cn/main/news/viewInfo Common/48988dda62fa0418bc7107fe7282df58.
